Replies to post #30030 on MannKind Corp. (MNKD)

[parkourstar]

The ONLY thing "brewing" right now is the size of the massive dilution that necessarily will occur before the end of the quarter.

Of course, it may be that MNKD will want to get another 140 million shares authorized before they seek the dilution.

[$Pistol Pete$]

$MNKD MannKind Corporation to Present at Upcoming Conferences

Source: GlobeNewswire Inc.

MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will present at upcoming conferences.
Rodman & Renshaw 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 9:35 am (ET) at the St. Regis Hotel in New York City

Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, 2018 at 1:40 pm (ET) at the Intercontinental New York Barclay Hotel in New York City
Presenting from the Company will be its Chief Executive Officer, Michael Castagna.

Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at http://www.mannkindcorp.com.

About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

Company Contact:
Rose Alinaya
SVP Investor Relations
818-661-5000
[e-mail]

Source: MannKind Corporation


Primary Logo